http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Immediate Postoperative Epidural Hematomas Adjacent to the Craniotomy Site
Jeon, Jin-Soo,Chang, In-Bok,Cho, Byung-Moon,Lee, Ho-Kook,Hong, Seung-Koan,Oh, Sae-Moon The Korean Neurosurgical Society 2006 Journal of Korean neurosurgical society Vol.39 No.5
Objective : The authors present eight cases of immediate post-operative epidural hematomas[EDHs] adjacent to the craniotomy site, describe clinical details of them, and discuss their pathogenesis. Methods : Medical records of eight cases were retrospectively reviewed and their clinical data, operation records, and radiological findings analyzed. Any risk factors of the EDHs were searched. Results : In 5 of 8 cases, adjacent EDHs developed after craniotomies for the surgical removal of brain tumors. Three cases of adjacent EDHs developed after a pterional approach and neck clipping of a ruptured anterior communicating artery aneurysm, a ventriculoperitoneal shunt, and a craniotomy for a post-traumatic EDH, respectively. In all eight cases, brain computed tomography[CT] scans checked immediately or a few hours after the surgery, revealed large EDHs adjacent to the previous craniotomy site, but there was no EDH beneath the previous craniotomy flap. After emergent surgical removal of the EDHs, 7 cases demonstrated good clinical outcomes, with one case yielding a poor result. Conclusion : Rapid drainage of a large volume of cerebrospinal fluid or intra-operative severe brain collapse may separate the dura from the calvarium and cause postoperative EDH adjacent to the previous craniotomy site. A high-pressure suction drain left in the epidural space may contribute to the pathogenesis. After the craniotomy for brain tumors or intracranial aneurysms, when remarkable brain collapse occurs, an immediate postoperative brain CT is mandatory to detect and adequately manage such unexpected events as adjacent EDHs.
Seong Kook Jeon,Jin Suk Park,Jeong Gu Kang,Sun Hee Kim,Nan Ee Lee,Jung Mi Lee,Subin Moon,Dae In Ha,Do Yon Kim,Jeong-Heon Ko,Yong-Sam Kim 한국당과학회 2017 한국당과학회 학술대회 Vol.2017 No.01
Genome editing technology promises to provide versatile tools for the generation of various model cell lines, plants and animals as well as for gene therapy by gene-editing in a target-specific manner. To date, three distinct modes of genome editing technologies have been introduced and extensively investigated in experimental settings, and attempted for use in clinical settings. Despite the revolutionized efficiency and sophistication in gene editing owing to development of CRISPR/Cas9, there remains technical limitations for currently available programmable nucleases in the routine use in experimental and clinical settings. Here, we introduce a universal genome editing technology (UGET) that relies on gene targeting through simple base pairings between a 20-28 nt nucleotide probe and a stretch of single-strand target DNA at the replication fork. UGET has no target limitations, shows lower-than-expected off-target incidence, is straightforward to use, and is compatible to gene correction via HDR. In particular, an overall construct size is less than 2.3kb, which means a high flexibility for use in gene therapy using viral vectors including adenovirus-associated viruses as well as for agrobacterium-based transformation in plants.
조국희(Kook-Hee Cho),조문수(Moon-Soo Cho),전태원(Tae-Won Jeon),정종훈(Jong-Hoon Cheong) 한국조명·전기설비학회 2006 한국조명·전기설비학회 학술대회논문집 Vol.2006 No.11월
부싱의 형상에 따라 전계 분포를 비교하여 가장 효율적인 전계분포가 이루어지도록 형상을 설계하고자 하였다. 전극 길이의 변화로 벡터 분포도는 0.7[%], 전계 분포도는 약 21~26[%], 전위 분포도는 약 25~39[%]의 절연 성능을 향상시킬 수 있었다. 고압부 절연물 두께의 변화로 벡터 분포도는 2[%], 전계 분포도는 약 23~43[%], 전위 분포도는 약 28~60[%]의 절연 성능을 향상시킬 수 있었다.
The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma
Lee, Youngjoo,Jeon, Jae Hyun,Goh, Sung-Ho,Roh, Hanseong,Yun, Ji-Young,Kwon, Nak-Jung,Choi, Jin Ho,Yang, Hee Chul,Kim, Moon Soo,Lee, Jong Mog,Lee, Geon Kook,Han, Ji-Youn Elsevier 2019 Lung cancer Vol.136 No.-
<P><B>Abstract</B></P> <P><B>Objectives</B></P> <P>Accumulating evidence reveals the association between the risk of never-smoker lung cancer and family history of cancer. However, the clinicogenomic effect of family history of cancer in never-smoker lung cancer remains unknown.</P> <P><B>Material and methods</B></P> <P>We screened 3,241 lung cancer patients who (a) underwent curative resection at National Cancer Center (Goyang, Korea) between 2001–2014, and (b) completed a pre-designed interview about family/smoking history at the time of diagnosis and identified 604 female never smoker lung adenocarcinoma. A positive family history of cancer [categorized as pulmonary cancer (FH-PC) or non-pulmonary cancer (FH-NPC)] was defined as a self-reported history of cancer in first-degree relatives. Survival data were followed up until January 2017. Multiplexed targeted next-generation sequencing was performed for genetic profiling.</P> <P><B>Results</B></P> <P>Of 604 patients, 29.1% (n = 176) had a FH, including 132 (21.9%) with FH-NPC and 44 (7.3%) with FH-PC. Patients with the FH-NPC had a higher proportion of young patients (≤45 years) than those without the FH-NPC (FH-NPC, FH-PC, and no FH; 13.6%, 2.3%, and 8.2%, respectively; <I>P</I> = 0.032). Patients with the FH-NPC had an increased risk of recurrence (hazard ratio [HR]: 1.90; 95% confidence interval [CI]: 1.40–2.56; <I>P<</I>0.001) and death (HR: 1.67; 95% CI: 1.18–2.37; <I>P=</I>0.004). In contrast, the FH-PC had no prognostic effect on recurrence (HR: 1.23; 95% CI: 0.71–2.15; <I>P = 0.456</I>) and death (HR: 0.93; 95% CI: 0.45–1.91; <I>P=</I>0.838). Among three driver oncogene alterations, <I>EGFR</I> mutation was significantly associated with the FH-PC (53.8%, 84.1%, and 65.8%, respectively; <I>P</I> = 0.016), <I>ALK</I>/<I>ROS1</I>/<I>RET</I> fusions was significantly associated with the FH-NPC (13.7%, 0.0%, and 5.0%, respectively; <I>P</I> = 0.004), but <I>KRAS</I> mutation was not associated with any type of the FH (13.8% vs. 6.0% vs. 7.8%, respectively; <I>P</I> = 0.288).</P> <P><B>Conclusion</B></P> <P>The type of family history of cancer was associated with distinct clinocogenomic subtypes and prognosis of never-smoker lung adenocarcinoma.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Family history of cancer is related to distinct subtypes of never smoker lung cancer. </LI> <LI> <I>ALK/ROS1/RET</I> fusions are enriched in patients with family history of nonlung cancer. </LI> <LI> <I>EGFR</I> mutations are enriched in patients with family history of lung cancer. </LI> <LI> Family history of nonlung cancer is associated with poor prognosis after operation. </LI> </UL> </P>
Shin, Jae Kook,Cheon, Jae Hee,Lim, Joon Seok,Park, Jae Jun,Moon, Chang Mo,Jeon, Soung Min,Lee, Jin Ha,Hong, Sung Pil,Kim, Tae Il,Kim, Won Ho Blackwell Publishing Asia 2011 Journal of gastroenterology and hepatology Vol.26 No.5
<P><B>Abstract</B></P><P><B>Background and Aim: </B> Computed tomography enterography (CTE) is a promising modality for small bowel imaging. However, the role of CTE in the evaluation of obscure gastrointestinal bleeding (OGIB) has not been established. We investigated the efficacy of CTE in diagnosing OGIB and the long‐term outcomes based on CTE findings, with special reference to negative CTE.</P><P><B>Methods: </B> A total of 63 consecutive patients who had undergone CTE for OGIB were enrolled, and their pre‐ and post‐CTE clinical data were collected. “Specific treatments” were defined as treatments directly aimed at resolving presumed bleeding causes, including hemostasis and operation, while “non‐specific treatments” were defined as symptomatic treatments for anemia.</P><P><B>Results: </B> Among 60 patients for whom long‐term follow‐up data were available, positive lesions were found in 16 patients (26.7%). The overall rebleeding rate was 21.7% during a mean follow up of 17.6 ± 4.7 months. There was no significant difference in the cumulative rebleeding rates between patients with positive and negative CTE results (<I>P</I> = 0.241). All patients who received specific treatments after CTE did not rebleed (0/8). In positive CTE patients, specific treatments significantly reduced the rebleeding rate (<I>P</I> = 0.023).</P><P><B>Conclusions: </B> CTE has a high rate of detecting overt OGIB. However, negative CTE results do not predict lower long‐term rebleeding, and such patients with OGIB should be closely observed. In patients with positive CTE, more vigorous management significantly reduces the incidence of rebleeding.</P>
Shin, Jae Kook,Cheon, Jae Hee,Kim, Eun Sook,Yoon, Jin Young,Lee, Jin Ha,Jeon, Soung Min,Bok, Hyun Jung,Park, Jae Jun,Moon, Chang Mo,Hong, Sung Pil,Lee, Yong Chan,Kim, Won Ho The Korean Academy of Medical Sciences 2010 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.25 No.7
<P>The purpose of this study is to evaluate the predictive capability of anorectal physiologic tests for unfavorable outcomes prior to the initiation of biofeedback therapy in patients with dyssynergic defecation. We analyzed a total of 80 consecutive patients who received biofeedback therapy for chronic idiopathic functional constipation with dyssynergic defecation. After classifying the patients into two groups (responders and non-responders), univariate and multivariate analyses were performed to determine the predictors associated with the responsiveness to biofeedback therapy. Of the 80 patients, 63 (78.7%) responded to biofeedback therapy and 17 (21.3%) did not. On univariate analysis, the inability to evacuate an intrarectal balloon (<I>P</I>=0.028), higher rectal volume for first, urgent, and maximal sensation (<I>P</I>=0.023, <I>P</I>=0.008, <I>P</I>=0.007, respectively), and increased anorectal angle during squeeze (<I>P</I>=0.020) were associated with poor outcomes. On multivariate analysis, the inability to evacuate an intrarectal balloon (<I>P</I>=0.018) and increased anorectal angle during squeeze (<I>P</I>=0.029) were both found to be independently associated with a lack of response to biofeedback therapy. Our data show that the two anorectal physiologic test factors are associated with poor response to biofeedback therapy for patients with dyssynergic defecation. These findings may assist physicians in predicting the responsiveness to therapy for this patient population.</P>